Promising Trial

PARP inhibitors finally have some proof, writes Derek Lowe at In the Pipeline. He notes that the drug class has had its ups and downs, as PARP inhibitors developed by various companies haven't always done well in trials — or even always been PARP inhibitors.

But Lowe reports that Tesaro announced yesterday that neraparib, which it licensed from Merck, has shown promising results in ovarian cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Gene drives might run into biological resistance, the Economist reports.

Forensic experts exhumed painter Salvador Dalí's body to collect DNA for a paternity test, CBS News reports.

Yale Environment 360 writes that synthetic and conservation biologists aren't always on the same wavelength, but they are trying to reach an understanding.

In Science this week: full CRISPR locus integration complex structure, and more.